001024009 001__ 1024009
001024009 005__ 20250204113813.0
001024009 0247_ $$2doi$$a10.1093/neuonc/noae049
001024009 0247_ $$2ISSN$$a1522-8517
001024009 0247_ $$2ISSN$$a1523-5866
001024009 0247_ $$2pmid$$a38466087
001024009 0247_ $$2WOS$$aWOS:001196533900001
001024009 037__ $$aFZJ-2024-01908
001024009 082__ $$a610
001024009 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$eCorresponding author$$ufzj
001024009 245__ $$aChallenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group
001024009 260__ $$aOxford$$bOxford Univ. Press$$c2024
001024009 3367_ $$2DRIVER$$aarticle
001024009 3367_ $$2DataCite$$aOutput Types/Journal article
001024009 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721222121_1234
001024009 3367_ $$2BibTeX$$aARTICLE
001024009 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001024009 3367_ $$00$$2EndNote$$aJournal Article
001024009 520__ $$aBrain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
001024009 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001024009 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001024009 7001_ $$0P:(DE-HGF)0$$aKaufmann, Timothy J$$b1
001024009 7001_ $$0P:(DE-HGF)0$$aVollmuth, Philipp$$b2
001024009 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b3
001024009 7001_ $$00000-0001-5563-2871$$aSmits, Marion$$b4
001024009 7001_ $$0P:(DE-HGF)0$$aVeronesi, Michael C$$b5
001024009 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b6
001024009 7001_ $$0P:(DE-HGF)0$$aRudá, Roberta$$b7
001024009 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b8
001024009 7001_ $$0P:(DE-HGF)0$$aHattingen, Elke$$b9
001024009 7001_ $$0P:(DE-HGF)0$$aLaw, Ian$$b10
001024009 7001_ $$0P:(DE-HGF)0$$aHutterer, Markus$$b11
001024009 7001_ $$00000-0002-9204-7038$$aSoffietti, Riccardo$$b12
001024009 7001_ $$0P:(DE-HGF)0$$aVogelbaum, Michael A$$b13
001024009 7001_ $$0P:(DE-HGF)0$$aWen, Patrick Y$$b14
001024009 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b15
001024009 7001_ $$0P:(DE-HGF)0$$aTonn, Joerg-Christian$$b16
001024009 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae049$$gp. noae049$$n7$$p1181-1194$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/Invoice_SOA24LT002807.pdf
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/Invoice_SOA24LT002807.gif?subformat=icon$$xicon
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/Invoice_SOA24LT002807.jpg?subformat=icon-1440$$xicon-1440
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/Invoice_SOA24LT002807.jpg?subformat=icon-180$$xicon-180
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/Invoice_SOA24LT002807.jpg?subformat=icon-640$$xicon-640
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/PDF.pdf$$yRestricted
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/PDF.gif?subformat=icon$$xicon$$yRestricted
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/PDF.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/PDF.jpg?subformat=icon-180$$xicon-180$$yRestricted
001024009 8564_ $$uhttps://juser.fz-juelich.de/record/1024009/files/PDF.jpg?subformat=icon-640$$xicon-640$$yRestricted
001024009 8767_ $$8SOA24LT006917$$92024-06-15$$a1200204639$$d2024-06-20$$eColour charges$$jZahlung erfolgt
001024009 8767_ $$8SOA24LT002807$$92024-03-12$$a1200208029$$d2024-11-04$$eHybrid-OA$$jZahlung erfolgt
001024009 909CO $$ooai:juser.fz-juelich.de:1024009$$popenCost$$pOpenAPC$$pVDB
001024009 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b0$$kFZJ
001024009 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b3$$kFZJ
001024009 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b6$$kFZJ
001024009 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001024009 9141_ $$y2024
001024009 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001024009 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
001024009 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
001024009 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
001024009 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001024009 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
001024009 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
001024009 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
001024009 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
001024009 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
001024009 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001024009 920__ $$lyes
001024009 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001024009 980__ $$ajournal
001024009 980__ $$aVDB
001024009 980__ $$aI:(DE-Juel1)INM-3-20090406
001024009 980__ $$aAPC
001024009 980__ $$aUNRESTRICTED
001024009 9801_ $$aAPC